Metastatic Bone Pain Palliation using 177 Lu-Ethylenediaminetetramethylene Phosphonic Acid
177 Lu-ethylenediaminetetramethylene phosphonic acid (EDTMP) is presently suggested as an excellent bone seeking radionuclide for developing metastatic bone pain (MBP) palliation agent owing to its suitable nuclear decay characteristics. To find the exact dosage and its efficiency, this clinical stu...
Saved in:
| Main Authors: | Mehrosadat Alavi, Shapour Omidvari, Alireza Mehdizadeh, Amir Jalilian, Ali Bahrami-Samani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2015-04-01
|
| Series: | World Journal of Nuclear Medicine |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.157124 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of tumour segmentation methods for dosimetry in [177Lu]Lu-PSMA I&T treated patients with metastatic castration resistant prostate cancer
by: Peter Frøhlich Staanum, et al.
Published: (2025-07-01) -
First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma
by: Wendy Delbart, et al.
Published: (2025-07-01) -
On the feasibility of producing Lu-177 in the IEA-R1 reactor via the direct route
by: Guilherme Soares Zahn, et al.
Published: (2021-04-01) -
Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors
by: Hyunpil Sung, et al.
Published: (2025-08-01) -
Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy
by: Felix L. Herr, et al.
Published: (2025-08-01)